

Advice on the Patient Workup

Performing cataract surgery on a patient with uveitis requires careful preoperative planning and evaluation.

BY JENNIFER H. HUNG, MD, AND RICHARD E. BRAUNSTEIN, MD

The uveitic cataract patient deserves special attention, including careful preoperative management. Ophthalmologists must take into account potential peri- and postoperative challenges. The cataract may have developed due to the inflammatory disease, as in juvenile idiopathic arthritis, or secondary to treatment with corticosteroids. Although all types of cataract may occur in uveitic patients, the posterior subcapsular cataract is the most common presentation (Figure 1).¹

ESTABLISHING THE DIAGNOSIS

Physicians can use the patient's medical history along with laboratory information to diagnose most types of uveitis.² In general, the less inflammation present at the time of surgery, the better the overall clinical prognosis and the lower the possibility of severe postoperative complications.³

Determining the type, location (anterior and/or posterior), and cause of uveitis is important for anticipating the course of the disease, treatment response, and the rate of complications. For example, patients with uveitis sec-



Figure 1. A dense subcapsular plaque best seen after the cataract's removal.

“The expected course of the inflammatory disease and level of control prior to cataract surgery will ultimately affect the timing of the procedure.”

ondary to juvenile idiopathic arthritis tend to have more postoperative inflammation than those with idiopathic etiologies.^{1,2} Ocular toxoplasmosis may be reactivated after cataract surgery, so pre- and postoperative treatment is recommended.⁴ Understanding the expected course of the inflammatory disease and level of control prior to cataract surgery will ultimately affect the timing of the procedure, perioperative medical management, and the decision whether or not to implant an IOL.

OPHTHALMIC EXAMINATION OF THE UVEITIC CATARACT

Overview

Generally, the goal of cataract surgery is successful visual rehabilitation. In the uveitic eye, the postoperative visual outcome depends on the surgery itself as well as preexisting damage from pre- and postoperative inflammation. A careful and complete ophthalmic examination spanning the anterior to posterior segments is critical for pre- and postoperative planning.

Slit-lamp Examination

Evidence of inflammatory sequelae on the corneal endothelium such as keratic precipitates (KP) facilitate the diagnosis of uveitis (eg, mutton-fat KP in sarcoidosis vs stellate KP in Fuchs heterochromic cyclitis [FHC]).³

The slit-lamp examination can also reveal multiple potential surgical complications. On the cornea, band keratopathy from chronic inflammation or scarring from prior herpetic disease may limit visualization. In some

cases, it may be necessary to manage the corneal opacity by means such as chelation with calcium ethylenediaminetetraacetic acid after epithelial debridement to permit visualization.³

Pupillary Examination

A careful pupillary examination is critical to identifying poor dilation as well as posterior synechiae. A miotic pupil may necessitate the intraoperative use of iris hooks or pupil-expanding ring devices. Posterior synechiae may require gentle synechiolysis prior to cataract extraction to facilitate pupillary dilation and the surgeon's access to the anterior lens capsule (Figure 2).¹⁻³

Patients with chronic uveitis may develop a cyclitic membrane that extends from the ciliary body over the back surface of the lens. The surgeon may need to excise the membrane with scissors. Care must be taken when pulling a cyclitic membrane, because ciliary body detachment may result, leading to hypotony and phthisis.³ Vascularized membranes may also develop over the entire pupillary surface. Some bleeding may occur during removal, but these tissues and cells must be removed for visualization.¹⁻³ Finally, iris sphincter atrophy may occur in patients with FHC, and it is considered a risk factor for increased postoperative inflammation.¹ The surgeon may elect to perform a peribulbar or retrobulbar block if he or she expects that manipulation of the iris will be extensive.²

“The ophthalmologist should proceed conservatively, and waiting for inflammation to subside is prudent.”

Gonioscopy

Frequently linked to uveitis, glaucoma can result from blockage of the angle structures or angle closure from peripheral anterior synechiae. Additionally, special consideration must be given to patients who are steroid responders. Although steroid use is often necessary, these agents may contribute to elevated IOP in this patient population.³ The glaucoma workup should include gonioscopy to evaluate the angle for anterior synechiae or angle vessels as in FHC.² Vessels in the angle may result in a transient intra- and postoperative hemorrhage.⁵ Iris bombé can be treated with surgical peripheral (possibly sectoral) iridectomy, because persistent inflammation may compromise the patency of laser iridectomies.

The indication for glaucoma surgery is the same as for any other glaucoma patient, but the postoperative



Figure 2. The lysis of synechiae via gentle dissection with the viscoelastic cannula.

course in uveitic eyes is more often complicated by scarring due to inflammation.³ The use of prostaglandin analogues should be avoided if possible to avoid provoking inflammation.

Dilated Fundus Examination and Ultrasonography

Physicians should perform a dilated fundus examination to identify posterior segment disease. In addition to glaucoma, the uveitic eye is prone to the development of cystoid macular edema, optic nerve disease, vasculitis, and neovascularization of the posterior pole. Because the presence of any of these conditions can limit the patient's postoperative visual potential, it is important to determine if the cataract or another simultaneous ocular pathology is causing the visual loss.¹ Patients with Behçet syndrome, for example, often develop optic nerve damage or vasculitis, so cataract surgery is unlikely to improve their vision.³

If the surgeon's view of the fundus is limited (eg, in an eye with a dense cyclitic membrane), ultrasonography will help him or her to establish the degree of vitreous opacities as well as to confirm the presence or absence of a concomitant retinal detachment.² If vitreous opacities are abundant, the surgeon may wish to perform a combined lensectomy and vitrectomy, because residual inflammation in the vitreous cavity can increase the frequency of uveitic recurrence.³

INDICATIONS FOR SURGERY

The decision to perform cataract surgery on a uveitic eye depends on the patient's visual disability, the degree of the cataract, and whether there is lens-induced inflammation. The ophthalmologist should proceed conservatively, and waiting for inflammation

CATARACT SURGICAL CARE IN THE PRESENCE OF INFLAMMATORY DISEASE

to subside is prudent. Unfortunately, lens-induced uveitis may necessitate more immediate cataract removal, even in the presence of active inflammation.

Cataract surgery in the uveitic patient thus falls into four clinical scenarios^{1,2,6}:

- active inflammation due to the leakage of lens proteins, as in phacoantigenic uveitis
- a visually significant cataract but well-controlled uveitis and anticipated good visual recovery
- a cataract and limited view of the fundus, affecting the evaluation and treatment of a possible fundus disorder
- a cataract preventing visualization for posterior segment surgery

In a quiet eye without active inflammation or sequelae from inflammation, cataract extraction does not pose a significant risk and often achieves a successful visual outcome, although careful postoperative control of inflammation is still critical. In lens-induced uveitis (phacolytic glaucoma, phacoantigenic uveitis, etc.), active inflammation can lead to poor outcomes intraoperatively and postoperatively. In phacolytic glaucoma, the lens is often fragile, and the capsule is easily ruptured. Due to the etiology of the uveitis, the lens must be removed in its entirety as soon as possible. Conversion to extracapsular cataract extraction may be necessary in these cases.³

CONCLUSION

Uveitic cataract patients require a thorough preoperative evaluation, control of inflammation, meticulous surgery, and careful postoperative management. With these steps, these individuals can undergo cataract extraction safely and successfully. ■

Richard E. Braunstein, MD, is the Miranda Wong Tang professor of clinical ophthalmology and chief of the Division of Anterior Segment at Columbia University in New York. Dr. Braunstein may be reached at (212) 305-3015; reb10@columbia.edu.



Jennifer H. Hung, MD, is the cornea fellow and instructor in clinical ophthalmology at Columbia University in New York. Dr. Hung may be reached at (212) 305-3015; jhh120@columbia.edu.



1. Foster CS, Rashid S. Management of coincident cataract and uveitis. *Curr Opin Ophthalmol*. 2003;14:1-6.
2. Van Gelder RN, Leveque TK. Cataract surgery in the setting of uveitis. *Curr Opin Ophthalmol*. 2009;20:42-45.
3. Smith RE, Nozak RA. Surgery in uveitis patients. In: Smith RE, Nozak RA, eds. *Uveitis: a Clinical Approach to Diagnosis and Management*. Baltimore, MD: Williams & Wilkins; 1989:115-126.
4. Bosch-Driessen LH, Plaisier MB, Stilma JS, et al. Reactivations of ocular toxoplasmosis after cataract extraction. *Ophthalmology*. 2002;109(1):41-45.
5. Bonfili AA, Curi ALL, Orefice F. Fuchs' heterochromic cyclitis. *Semin Ophthalmol*. 2005;20:143-146.
6. Okhravi N, Towler HMA, Lightman S. Cataract surgery in patients with uveitis. *Eye*. 2000;14:689-690.

RESTASIS®
(cyclosporine ophthalmic emulsion) 0.05%
Sterile, Preservative-Free

INDICATIONS AND USAGE

RESTASIS® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

CONTRAINDICATIONS

RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

WARNING

RESTASIS® ophthalmic emulsion has not been studied in patients with a history of herpes keratitis.

PRECAUTIONS

General: For ophthalmic use only.

Information for Patients

The emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration.

Do not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion.

RESTASIS® should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® ophthalmic emulsion.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Systemic carcinogenicity studies were carried out in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.

In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 1000 and 500 times greater, respectively, than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Cyclosporine has not been found mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes *in vitro* gave indication of a positive effect (i.e., induction of SCE).

No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 15,000 times the human daily dose of 0.001 mg/kg/day) for 9 weeks (male) and 2 weeks (female) prior to mating.

Pregnancy-Teratogenic Effects

Pregnancy category C.

Teratogenic Effects: No evidence of teratogenicity was observed in rats or rabbits receiving oral doses of cyclosporine up to 300 mg/kg/day during organogenesis. These doses in rats and rabbits are approximately 300,000 times greater than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.

Non-Teratogenic Effects: Adverse effects were seen in reproduction studies in rats and rabbits only at dose levels toxic to dams. At toxic doses (rats at 30 mg/kg/day and rabbits at 100 mg/kg/day), cyclosporine oral solution, USP, was embryo- and fetotoxic as indicated by increased pre- and postnatal mortality and reduced fetal weight together with related skeletal retardations. These doses are 30,000 and 100,000 times greater, respectively than the daily human dose of one drop (28 µL) of 0.05% RESTASIS® BID into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively, during organogenesis. These doses in rats and rabbits are approximately 17,000 and 30,000 times greater, respectively, than the daily human dose.

Offspring of rats receiving a 45 mg/kg/day oral dose of cyclosporine from Day 15 of pregnancy until Day 21 post partum, a maternally toxic level, exhibited an increase in postnatal mortality; this dose is 45,000 times greater than the daily human topical dose, 0.001 mg/kg/day, assuming that the entire dose is absorbed. No adverse events were observed at oral doses up to 15 mg/kg/day (15,000 times greater than the daily human dose).

There are no adequate and well-controlled studies of RESTASIS® in pregnant women. RESTASIS® should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

Cyclosporine is known to be excreted in human milk following systemic administration but excretion in human milk after topical treatment has not been investigated. Although blood concentrations are undetectable after topical administration of RESTASIS® ophthalmic emulsion, caution should be exercised when RESTASIS® is administered to a nursing woman.

Pediatric Use

The safety and efficacy of RESTASIS® ophthalmic emulsion have not been established in pediatric patients below the age of 16.

Geriatric Use

No overall difference in safety or effectiveness has been observed between elderly and younger patients.

ADVERSE REACTIONS

The most common adverse event following the use of RESTASIS® was ocular burning (17%).

Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Rx Only

 **ALLERGAN**

Based on package insert 71876US14B Revised February 2010

©2010 Allergan, Inc.

Irvine, CA 92612, U.S.A.

* marks owned by Allergan, Inc. APC66CG11

U.S. Patent 5,474,979

Made in the U.S.A.